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Comparaison des Algorithmes de Prévention Cardiovasculaire Suisse et Européen dans 
une Cohorte Suisse 
 
Contexte : En Suisse, la prévention cardiovasculaire est basée sur des recommandations 
émanant de deux sociétés savantes différentes : 1) le Groupe de travail Lipides et 
Athérosclérose (GSLA) » ; et 2) la Société Européenne de Cardiologie (ESC). Chacune fournit 
un score de risque cardiovasculaire (PROCAM pour le GSLA et SCORE pour l’ESC), ainsi 
qu’un algorithme de prise en charge, guidant les mesures de prévention en fonction du risque 
cardiovasculaire estimé. 
But : Notre but premier était de déterminer lequel, entre l’algorithme du GSLA et celui de 
l’ESC, était le plus performant pour prédire la survenue d’événements cardiovasculaires 
athérosclérotiques (ECVA), ainsi que leur propension respective à recommander la prescription 
de statines dans la population suisse. Notre deuxième but était de valider pour la Suisse les 
scores de risque du GSLA et de l’ESC, couramment utilisés en prévention primaire. 
Méthode : Les données sont basées sur une étude populationnelle prospective, la cohorte 
« CoLaus ». L’échantillon initial comprenait 6'733 personnes, âgées de 35 à 75 ans (54% de 
femmes), qui furent suivies durant 10 ans. Nous avons calculé les performances de 
discrimination et de calibration des algorithmes du GSLA et de l’ESC, et ainsi déterminé leurs 
capacités à prédire la survenue d’événements cardiovasculaires. 
Résultats : Des 6'733 participants de l’échantillon initial, 5'529 avaient des données complètes 
et furent inclus dans nos analyses. L’âge moyen (déviation standard, DS) était de 52.4 (10.6) 
ans. Durant un suivi moyen (DS) de 10.2 (1.7) ans, 370 (6.7%) participants présentèrent un 
ECVA. La sensibilité des algorithmes du GSLA et de l’ESC pour la prédiction d’ECVA étaient 
respectivement de 51.6% (IC 95%, 46.4-56.8) et de 58.6% (53.4-63.7). Les performances de 
discrimination et de calibration étaient similaires entre les algorithmes du GSLA et de l’ESC, 
avec des valeurs d’air sous la courbe de 0.78 (95% CI, 0.76-0.80) et de 0.79 (0.76-0.81), et des 
scores de Brier de 0.059 et de 0.041, respectivement. Parmi les 370 individus ayant présentés 
un ECVA, seulement 278 (75%) étaient éligibles pour un traitement par statine au début du 
suivi. Les performances prédictives des scores de risque du GSLA et de l’ESC étaient 
également similaires et bonnes, validant leur usage pour la population suisse en prévention 
cardiovasculaire primaire. 
Conclusion : Les algorithmes du GSLA et de l’ESC présentent des facultés similaires pour 
prédire la survenue d’événements cardiovasculaires en Suisse. Un quart des événements 
cardiovasculaires ont lieu chez des personnes identifiées à bas risque selon les 
recommandations actuelles, soulignant le besoin de développer des méthodes complémentaires 
pour améliorer les stratégies de prévention cardiovasculaire. 
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Comparison of Swiss and European risk
algorithms for cardiovascular prevention
in Switzerland
Hadrien Beuret1, Nadine Hausler1, David Nanchen2,
Marie Me´an1,3, Pedro Marques-Vidal1,3 and Julien Vaucher1,3
Abstract
Background: In Switzerland, two distinct algorithms are recommended for cardiovascular prevention: (a)
Arbeitsgruppe Lipide und Atherosklerose (AGLA); and (b) European Society of Cardiology (ESC). We validated and
determined which algorithm better predicts incident atherosclerotic cardiovascular disease and assessed statin eligibility
in Switzerland.
Design: A prospective population-based cohort.
Methods: We employed longitudinal data of the CoLaus study involving 6733 individuals, aged 35–75 years, with a
10-year follow-up. Using discrimination and calibration, we evaluated the predictive performance of the AGLA and ESC
algorithms for the prediction of atherosclerotic cardiovascular disease.
Results: From the 6733 initial participants, 5529 were analysed with complete baseline and follow-up data. Mean age (SD)
was 52.4 (10.6) years and 54% were women. During an average follow-up (SD) of 10.2 years (1.7), 370 (6.7%) participants
developed an incident atherosclerotic cardiovascular disease. The sensitivity of AGLA and ESC algorithms to predict ath-
erosclerotic cardiovascular disease was 51.6% (95% confidence interval (CI) 46.4–56.8) and 58.6% (53.4–63.7), respectively.
Discrimination and calibration were similar between the AGLA and ESC algorithms, with area under the receiver operating
characteristic curve values of 0.78 (95% CI 0.76–0.80) and 0.79 (0.76–0.81), and Brier scores of 0.059 and 0.041, respectively.
Among 370 individuals developing incident atherosclerotic cardiovascular disease, only 278 (75%) were eligible for statin
therapy at baseline, including 210 (57%) according to both algorithms, 4 (1%) to AGLA only and 64 (17%) to ESC only.
Conclusion: AGLA and ESC algorithms presented similar accuracy to predict atherosclerotic cardiovascular disease in
Switzerland. A quarter of adults developing atherosclerotic cardiovascular disease were not identified by preventive
algorithms to be eligible for statin therapy.
Keywords
Cardiovascular, prevention, risk score, myocardial infarction, guidelines, Switzerland
Received 2 October 2019; accepted 24 January 2020
Introduction
Cardiovascular disease (CVD) is the leading cause of
death worldwide, accounting for more than 17 million
deaths annually.1 In Switzerland, CVD also represents
a health and economic burden, with about one third
of all deaths attributable to CVD,2,3 and annual
direct costs corresponding to 16% of total health
expenditures.2,4
Prevention of CVD is based on the use of different
cardiovascular risk scores that were developed to assess
the cumulative effect of cardiovascular risk factors.
1Service of Internal Medicine, Lausanne University Hospital, Switzerland
2Center for Primary Care and Public Health (Unisante´), University of
Lausanne, Switzerland
3Faculty of Biology and Medecine, University of Lausanne, Switzerland
Corresponding author:
Hadrien Beuret, Department of Medicine, Lausanne University Hospital
(CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland.
Email: hadrien.beuret@gmail.com
European Journal of Preventive
Cardiology
0(00) 1–9
! The European Society of
Cardiology 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2047487320906305
journals.sagepub.com/home/cpr
 
These scores are recommended to identify patients who
would benefit the most from preventive measures,
including the use of statins.5–13 In Switzerland, cardio-
vascular prevention is based on two different guidelines:
(a) the International Atherosclerosis Society guidelines
(IAS), adopted by the Swiss Atherosclerosis
Association (in German Arbeitsgruppe Lipide und
Atherosklerose; AGLA);6,7,14 and (b) the 2016 guide-
lines of the European Society of Cardiology
(ESC).5,10,15 Both guidelines propose risk algorithms
and corresponding risk scores, using the AGLA score
(based on the PROCAM score recalibrated for
Switzerland) and the Systematic COronary Risk
Estimation (ESC-SCORE), recalibrated for Switzerland,
respectively (see Supplementary Table 1). Algorithms
allow risk prediction in all patients, including those at
very high risk (see Supplementary Figures 1 and 2). It is
noteworthy that the AGLA and ESC algorithms differ in
risk factors or thresholds of risk factors for identifying
individuals at high or very high cardiovascular risk.
Furthermore, the AGLA score predicts fatal and non-
fatal incident coronary events whereas the ESC-SCORE
estimates fatal CVD events (see Supplementary Table 1).
Currently, it remains unknown which of the two algo-
rithms and scores perform best in Switzerland.
Establishing which one has a better predictive accuracy
is important because implementation of preventive algo-
rithms can greatly impact the incidence of CVD as well as
the number of drugs used at large scale.
Using data of a prospective and population-based
Swiss cohort, the CoLaus study,16 our first aim was
to compare AGLA and ESC algorithms and validate
AGLA and ESC risk prediction models (i.e. AGLA
score and ESC-SCORE) for the estimation of cardio-
vascular risk. Second, we compared statin eligibility
according to the AGLA and ESC risk algorithms,
based on participants’ cardiovascular risk profile and
low-density lipoprotein (LDL) cholesterol levels.
Methods
Study population
The CoLaus study (www.colaus-psycolaus.ch) is a
Swiss population-based prospective cohort.16 Between
2003 and 2006, 6733 subjects (age range 35–75 years,
54% women) were recruited from a random sample of
the population of Lausanne, located in the French-
speaking part of Switzerland. The participation rate
amounted to 41%. The study was approved by the
institutional ethics committee of the University of
Lausanne and all participants provided written
informed consent. Participants were invited to attend
the outpatient clinic at the University Hospital of
Lausanne in the morning after an overnight fasting
for baseline clinical assessment, questionnaire comple-
tion and blood sample collection. Periodic surveys
of the whole cohort were conducted over a 13-year
follow-up. Relevant medical records of participants
who declared to have presented with a CVD and/or
CVD-related procedure during their lifetime were col-
lected. Information on cause of death was also pro-
spectively collected during the study period (see
clinical data collection in the Supplementary material).
Algorithms analysis
The AGLA and ESC risk algorithms are detailed in
Supplementary Figures 1 and 2.10,12
Participant selection. Participants were eligible for analysis
if complete information regarding variables of interest
(such as blood pressure, lipid and glycaemic values, or
smoking status) were available. Furthermore, those
refusing to partake in the 10-year follow-up were
excluded from analysis (see Supplementary Figure 3).
Outcomes and adjudication of cardiovascular events. As the
AGLA and ESC algorithms were designed to predict
different cardiovascular outcomes (see Supplementary
Table 1), the prediction performance of the two algo-
rithms was compared using a common set of clinical
cardiovascular outcomes, namely atherosclerotic cardio-
vascular disease (ASCVD), as already performed17 and
recommended by the 2019 American College of
Cardiology (ACC)/American Heart Association (AHA)
cardiovascular preventive guidelines.9,18,19 We defined
incident ASCVD as an episode of: (a) acute myocardial
infarction; (b) sudden cardiac death; (c) symptomatic
coronary artery disease with greater than 50% stenosis
(treated by percutaneous coronary intervention or cor-
onary artery bypass graft); and (d) fatal and non-fatal
ischaemic stroke (including transient ischaemic attack).
Peripheral artery disease was not included in ASCVD as
this outcome was not collected in the CoLaus study.
The occurrence of an incident ASCVD was prospect-
ively collected during the follow-up period. Participants
experiencing an ASCVD were censored for the rest of
the study period, preventing double counting of partici-
pants developing additional ASCVD. All cardiovascu-
lar events were independently adjudicated based on
largely established recommendations and definitions
(see Supplementary material). Myocardial infarction
was adjudicated by two independent cardiologists,
stroke by one neurologist, and deaths by two internists.
Statistical analysis
Participants’ characteristics were described according
to incident ASCVD. Categorical variables were
2 European Journal of Preventive Cardiology 0(00)
 
summarised as number of subjects with column
percentages, and continuous variables as means with
standard deviation (SD). Pearson chi-square (for cat-
egorical variables) or analysis of variance (ANOVA)
(for continuous variables) were used to evaluate differ-
ences in subjects’ baseline characteristics according to
the occurrence of ASCVD.
Performance of risk algorithms. To examine performance
of the whole AGLA and ESC algorithms, we included
people at high and very high cardiovascular risk at
baseline, comprising those with pre-existing cardiovas-
cular disease (CVD) or equivalent (see Supplementary
Table 1 and Supplementary Figures 1 and 2). This
approach holds the potential to represent a better
assessment of the entire risk algorithms and of their
public health impact.
We assessed the predictive accuracy of the AGLA
and ESC algorithms to assign individuals who devel-
oped ASCVD correctly into the high/very high risk cat-
egory, with regard to low/intermediate categories of
risk. For individuals requiring a risk estimation based
on the computation of score (i.e. without prevalent
ASCVD or equivalent condition; see Supplementary
Figures 1 and 2), we systematically used recalibrated
versions of the AGLA score and ESC-SCORE.5–7,14,15
Discrimination and calibration were computed.
Discrimination was expressed as area under the receiver
operating characteristic (AUROC) curve and tested
how well both algorithms distinguished high/very high
risk subjects from those at low and intermediate risk.
Calibration refers to the agreement between the pre-
dicted and observed rate of ASCVD and was assessed
by the Brier score and Hosmer–Lemeshow statistic.
In addition, goodness of fit was assessed with Akaike
information criterion (AIC) and Bayesian information
criterion (BIC). We derived calibration plots of the
AGLA and ESC algorithms from Cox prediction
models (using Stata command ‘stmp2’, fitting flexible
parametric survival models), with partition of partici-
pants into 10 deciles of risk. Calibration plots were
drawn using Stata command ‘pmcalplot’.
As transient ischaemic attacks, not necessarily related
to atherosclerosis, represented 41% of ischaemic strokes,
we conducted an additional test by removing them from
the analysis. We also performed a sensitivity analysis by
excluding participants under statin therapy at baseline
and reaching LDL-cholesterol targets.
Risk prediction model analysis. We additionally validated
the AGLA and ESC risk prediction models (i.e. AGLA
score and ESC-SCORE) using each score-specific car-
diovascular outcome (i.e. 10-year risk of major coron-
ary events and cardiovascular death, respectively) after
the exclusion of high and very high risk individuals
(see Supplementary Figures 1, 2 and 3). Detailed
risk prediction model analysis is described in the
Supplementary material.
Eligibility for statin therapy. We determined the number of
participants eligible for statin treatment according to
the AGLA and ESC algorithms, based on cardiovascu-
lar risk estimation and LDL-cholesterol levels.10,12
Participants were considered as eligible for statin
therapy when LDL-cholesterol levels were equal to or
higher than the recommended targets for each
category of risk (see Supplementary Figures 1 and
2).10,12 Overlap between eligibility for statin therapy
and incident ASCVD was presented as a Venn
diagram. It is noteworthy that treating physicians
were not implicated in any step of the study and the
prescription of lipid-lowering therapy was left to their
discretion.
All statistical analyses were performed using Stata
15.1 (Stata Corp, College Station, TX, USA).
Results
From the 6733 participants of the initial CoLaus study,
166 (2.5%) were excluded because of missing informa-
tion on variables of interest, and 1038 (15.4%) refused
to partake in the 10-year follow-up (see Supplementary
Figure 3). Thus, 5529 participants (54.3% women) were
available for the analyses.
The mean age of participants was 52.4 years (SD
10.6) and the mean follow-up was 10.2 years (SD 1.7)
(Table 1). A total of 511 (9.2%) participants were on
statin therapy at baseline and 166 (2.9%) had prior
ASCVD. The AGLA and ESC algorithms, respectively,
classified 19.3% and 21.4% of participants into the
high or very high risk categories (Table 2).
During the 10.2 years follow-up, 370 (6.7%) partici-
pants developed an incident ASCVD, comprising
94 acute myocardial infarctions or sudden cardiac
deaths, 151 symptomatic coronary artery diseases treated
by revascularisation, 125 fatal and non-fatal ischaemic
strokes, including 51 transient ischaemic attacks.
Among the 222 participants who died during the study
period, 27 (12%) of them died from ASCVD. Individuals
who developed ASCVD were on average 10 years older,
more likely to bemen, have diabetes and be a smoker, and
had higher blood pressure compared with participants
without incident ASCVD (Table 1).
Performance of risk algorithms (n¼ 5529)
Sensitivity of the AGLA and ESC algorithms to predict
ASCVD were 51.6% (95% confidence interval (CI)
46.4–56.8) and 58.6% (95% CI 53.4–63.7), respectively.
The negative predictive values (95% CI) were 96.0%
Beuret et al. 3
 
Table 1. Participant characteristics at baseline, in risk algorithm analysis, by incident ASCVD (n¼ 5529).
Incident ASCVD
All No Yes P value
N (%) 5529 5159 (93.3) 370 (6.7)
Age (years) 52.4 10.6 51.8 10.4 61.1 9.6 <0.001
Male 2526 (45.7%) 2274 (44.1%) 252 (68.1%) <0.001
Parental history of MI 308 (5.6%) 283 (5.5%) 25 (6.9%) 0.303
Smoking status <0.001
Never 2262 (40.9%) 2162 (41.9%) 100 (27.0%)
Former 1836 (33.2%) 1677 (32.5%) 159 (43.0%)
Current 1431 (25.9%) 1320 (25.6%) 111 (30.0%)
Blood pressure (mm Hg)
Systolic 127.2 17.6 126.4 17.2 139.3 19.1 <0.001
Diastolic 79.0 10.8 78.7 10.7 82.9 11.8 <0.001
Lipids (mmol/L)
Total cholesterol 5.5 1.0 5.5 1.0 5.6 1.0 0.394
HDL-cholesterol 1.6 0.4 1.7 0.4 1.5 0.4 <0.001
LDL-cholesterol 3.3 0.9 3.3 0.9 3.4 0.9 0.047
Triglycerides 1.3 0.7 1.3 0.7 1.6 0.8 <0.001
Glucose (mmol/L) 5.5 1.0 5.5 0.9 6.0 1.8 <0.001
Diabetes mellitus (%) 389 (7.0%) 316 (6.1%) 73 (19.7%) <0.001
eGFR (CKD-EPI) (ml/min/1.73 m2) 85.7 15.0 86.1 14.9 80.2 16.1 <0.001
Prevalent chronic kidney disease
(eGFR <60 ml/min/1.73 m2)
228 (4.1%) 196 (3.8%) 32 (8.7%) <0.001
Prevalent ASCVD 162 (2.9%) 92 (1.8%) 70 (18.9%) <0.001
Statin therapy 511 (9.2) 406 (7.9%) 105 (28.4%) <0.001
Results express the number of participants (%) or mean SD. Percentages are expressed by row. P values were derived using Pearson chi-square or
analysis of variance when appropriate.
ASCVD: atherosclerotic cardiovascular disease; MI: myocardial infarction; HDL: high-density lipoprotein; LDL: low-density lipoprotein; eGFR: esti-
mated glomerular filtration rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration equation; SD: standard deviation.
Table 2. Distribution of risk categories at baseline in risk algorithm analysis, by incident ASCVD.
Risk categories
ASCVD
Total No Yes
N 5529 (100%) 5159 (93.3%) 370 (6.7%)
AGLA
Low (<10%) 4229 (76.5%) 4087 (96.6%) 142 (3.4%)
Intermediate (10 to <20%) 231 (4.2%) 194 (84.0%) 37 (16.0%)
High (20%) 550 (9.9%) 486 (88.4%) 64 (11.6%)
Very high 519 (9.4%) 392 (75.5%) 127 (24.5%)
ESC
Low (<1%) 3190 (57.7%) 3134 (98.2%) 56 (1.8%)
Intermediate (1 to <5%) 1153 (20.9%) 1056 (91.6%) 97 (8.4%)
High (5 to <10%) 592 (10.7%) 522 (88.2%) 70 (11.8%)
Very high (10%) 594 (10.7%) 447 (75.3%) 147 (24.7%)
Individuals were classified into four risk categories according to the predicted 10-year risk of major coronary event for
the AGLA algorithm and cardiovascular death for the ESC algorithm.
High and very high risk criteria are detailed in Supplementary Figures 1 and 2.
ASCVD: atherosclerotic cardiovascular disease; AGLA: Arbeitsgruppe Lipide und Atherosklerose; ESC: European Society
of Cardiology.
4 European Journal of Preventive Cardiology 0(00)
 
(95.4–96.5) for AGLA and 96.5% (95.9–97.0) for ESC
(Table 3). Discrimination was comparable for the
AGLA and ESC algorithms, with AUROC (95% CI)
of 0.78 (0.76–0.80) and 0.79 (0.76–0.81) (see Table 3
and Supplementary Figure 4).
Calibration of the AGLA and ESC algorithms
was also comparable with Brier scores of 0,059 and
0,041 for AGLA and ESC, respectively (Table 3). The
Hosmer–Lemeshow statistic showed P values of less
than 0.001 for both algorithms. For both AGLA and
ESC algorithms, calibrations plots showed a tendency
to overpredict ASCVD in the lower deciles of risk, and
an underprediction in intermediate to high deciles of
risk (Figure 1).
The predictive performances of the AGLA and
ESC algorithms remained consistent after removing
transient ischemic attacks from the analysis (see
Supplementary Table 2). The results also remained
similar after the exclusion of participants under statin
therapy at baseline and reaching LDL-cholesterol tar-
gets (see Supplementary Table 3).
Risk prediction models analysis (n¼ 4254 for AGLA
score and 4479 for ESC-SCORE)
Patient characteristics and distribution of risk cate-
gories for the risk prediction model analysis are pre-
sented in Supplementary Tables 4 and 5. The AGLA
score and ESC-SCORE presented valid predictive
performances with very high negative predictive
values (99.1% and 99.8%, respectively) and good dis-
crimination (AUROC, 0.80 and 0.87, respectively) (see
Supplementary Table 6). The ESC-SCORE presented a
marginally higher discrimination and sensitivity for its
specific outcome (CVD death).
Eligibility for statins (n¼ 5529)
According to the AGLA and ESC algorithms, 1206
(21.8%) and 1917 (34.7%) participants were eligible
for statin therapy, respectively. There was a substantial
overlap between the AGLA and ESC algorithms, with
1074 participants eligible for statins according to both
algorithms (Figure 2). Concerning the 370 individuals
who developed ASCVD, 210 (57%) were eligible for
statins according to both algorithms, 274 (74%)
according to the ESC algorithm, 214 (58%) according
to the AGLA algorithm. However, 92 (25%) adults
who developed ASCVD were not eligible for statins
according to the algorithms.
Discussion
Using a contemporary population-based cohort with a
10-year follow-up, our findings showed that the AGLA
and ESC algorithms had similar accuracy to predict a 10-
year risk of ASCVD in the Swiss population. We also
validated the AGLA and ESC risk prediction models in
Switzerland (i.e. AGLA and ESC scores) for cardiovas-
cular primary prevention. Full compliance with algo-
rithms for statin therapy would result in a higher
number of statin prescriptions based on the ESC risk
algorithm compared to AGLA’s. However, neither of
the two risk algorithms advocated statin use for a quarter
of adults who developed ASCVD. This implied that car-
diovascular prevention should be refined, through the use
Table 3. Performance of the AGLA and ESC risk algorithms to identify incident ASCVD (n¼ 5529).
AGLA (95% CI) ESC (95% CI)
Sensitivity 51.6% (46.4–56.8) 58.6% (53.4–63.7)
Specificity 83.0% (81.9–84.0) 81.2% (80.1–82.3)
Positive predictive value 17.9% (15.6–20.3) 18.3% (16.1–20.6)
Negative predictive value 96.0% (95.4–96.5) 96.5% (95.9–97.0)
Discrimination
AUROC 0.78 (0.76–0.80) 0.79 (0.76–0.81)
Calibration
Brier 0.059 0.041
Hosmer–Lemeshow (P value) <0.001 <0.001
Model fit
AIC 5813 5763
BIC 5820 5770
The AGLA and ESC risk algorithms were dichotomised into high/very high versus low/intermediate categories of risk.
ASCVD: atherosclerotic cardiovascular disease; AGLA: Arbeitsgruppe Lipide und Atherosklerose score; ESC: European
Society of Cardiology; CI: confidence interval; AUROC: area under the receiver operating characteristic; AIC: Akaike
information criterion; BIC: Bayesian information criterion.
Beuret et al. 5
 
of complementary approaches (for example, genome-
wide polygenic genetic risk scores or blood markers,
such as lipoprotein (a)).
In Switzerland, cardiovascular prevention is based
on the AGLA and ESC algorithms and their corres-
ponding risk scores (AGLA score and ESC-SCORE).
These scores have been developed in several European
populations and recalibrated for Switzerland.5–7,10,14,15
Switzerland is considered as a low cardiovascular risk
country, with a prevalence of cardiovascular risk fac-
tors and disease rates similar to France, Italy,
Germany, Spain, Portugal, the United Kingdom and
The Netherlands.20,21 Our results showed that both
algorithms were comparable and that the AGLA
score and ESC-SCORE are valid for use in
Switzerland. Previous studies,8,22 comparing the ESC-
SCORE in different European populations, have shown
similar discrimination ability as in our study, with
AUROC values ranging from 0.65 to 0.85, compared
to 0.87 (95% CI 0.81–0.94) in our study. For the
PROCAM score (used to derive the Swiss AGLA
score), AUROCs were lower, ranging from 0.61 to
0.74 in European populations,8,22 compared to 0.80
(95% CI 0.74–0.86) in our Swiss population. Overall,
our results also confirmed findings from a recent
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Figure 1. Predicted and observed ASCVD by algorithms. Calibration plots of cardiovascular risk score-specific Cox prediction
model in the algorithms analysis (n¼ 5529). Observed ASCVD in the algorithms analysis was calculated using Kaplan–Meier estimates.
Participants are divided into 10 deciles of risk represented by triangles. Vertical bars indicate 95% confidence intervals. ASCVD:
atherosclerotic cardiovascular disease; AGLA: Arbeitsgruppe Lipide und Atherosklerose score; ESC: European Society of Cardiology.
Total sample (N = 5529)
57%
25%
1%
17%
AGLA (N = 1206)
ASCVD (N = 370)
ESC (N = 1917)
Figure 2. Statin eligibility according to the AGLA and ESC risk
algorithms and incident ASCVD. The red and blue circles rep-
resent the proportional number of participants eligible to statin
according to the AGLA and ESC algorithms, respectively. The
yellow circle represents the participants who developed an
ASCVD during the 10-year follow-up. ASCVD: atherosclerotic
cardiovascular disease; AGLA: Arbeitsgruppe Lipide und
Atherosklerose; ESC: European Society of Cardiology.
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meta-analysis showing that the performance of scores
can be equalised after adequate recalibration.17
Only a third of individuals experiencing major coron-
ary events or dying from cardiovascular causes were
classified at high or very high risk according to the
AGLA-score and ESC-SCORE, respectively. Another
Swiss study found similar results by retrospectively
assessing the risk estimation and statin eligibility
among 3172 patients hospitalised for a first episode of
acute coronary syndrome.23 Only 35% and 37% of sub-
jects were identified as high risk according to the AGLA
score and ESC-SCORE, respectively. Furthermore, we
reported that 22% and 35% of participants would be
eligible for statin treatment according to the AGLA
and ESC algorithms, which is very close to the results
found in a recent European meta-analysis of existing
cardiovascular guidelines.17 However, we found that
among the 370 individuals who developed an incident
ASCVD over the 10-year follow-up period, a quarter
of them were not eligible for statin therapy by neither
of the two algorithms. This study thus adds to previous
evidence that current cardiovascular risk scores and
algorithms fail to identify a substantial number of indi-
viduals at high cardiovascular risk.14,23–25 This illustrates
the paradox that at a population level many ASCVDs
occur in people assumed to be at low cardiovascular
risk,10,25 simply because they are much more numerous.
This also highlights the need to study alternative cardio-
vascular prevention strategies by integrating comple-
mentary approaches (for example, genome-wide
polygenic genetic risk scores)26 or additional risk mar-
kers, such as coronary artery calcium score or lipopro-
tein(a) levels.10,18,19,25,27
Our study has several limitations. First there was a
relatively small number of certain incident ASCVDs,
such as cardiovascular deaths. This could have limited
the precision of some of our analyses, especially the risk
prediction models analysis. Nevertheless, the algo-
rithms analysis included 370 events, which is compar-
able to other studies.28 Second, population-based
studies may be affected by a ‘healthy volunteer’ selec-
tion bias,29 which could have reduced our ability to
capture actual cardiovascular risk in the Swiss popula-
tion. However, the cardiovascular event rate was com-
parable to previous studies conducted in similar settings
in other European cohorts.28,30 Third, our study was
purely observational and it is possible that a more
intensive preventive strategy would have translated
into a larger reduction of ASCVD. Fourth, our findings
are related to the French-speaking part of Switzerland
and might not be generalisable to other regions.
Nevertheless, the prevalence of cardiovascular risk fac-
tors is relatively homogeneous in Switzerland31,32 and
the incidence of ASCVD in the region where the
CoLaus study (that is, Canton de Vaud) was conducted
is similar to that in Switzerland. This reasonably allows
extrapolating our results to the whole country.33 Fifth,
peripheral artery disease was not included in the defin-
ition of ASCVD. As neither the AGLA nor ESC risk
algorithms included this outcome in their original equa-
tions, this minimises the risk that its exclusion reduced
the predictive performance of the equations.
Our study also has strengths. First, we used the
unique population-based cohort with a 10-year follow-
up for cardiovascular events in Switzerland. Second,
ASCVDs were prospectively collected and independently
adjudicated according to recent recommendations and
definitions, minimising the risk of misclassification.
Conclusion
Our findings, relying on contemporary and longitudinal
data of more than 5500 Swiss individuals, showed that
the AGLA and ESC cardiovascular preventive algo-
rithms had similar accuracy to predict ASCVD and
that both the AGLA and ESC scores were valid for
use in primary prevention of CVD in Switzerland.
However, our results confirmed that a significant pro-
portion of individuals developing CVD are not identi-
fied as at high risk by current algorithms, highlighting
the need for additional approaches to improve the per-
formance of cardiovascular prevention strategies.
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